Pharma Focus Asia

Cybeats Announces Trial Evaluation

Monday, March 27, 2023

Cybeats Technologies Corp announces the commencement of a trial evaluation with one of the top-3 largest software companies by total revenue, for Cybeats SBOM Studio.

The interest of a software company further reinforces the growing demand for SBOM consumption and management worldwide and increases the utility of SBOM Studio to address the global needs of the software supply chain.

Cybeats' SBOM Studio enables organisations to efficiently manage, distribute, and view their software bill of materials (SBOMs) in a single interface. By doing so, they can easily identify and address cybersecurity vulnerabilities, reduce the cost of protection, and improve compliance. SBOM Studio is specifically designed to support software producers and consumers who use open source and 3rd party software components and who are transitioning to more transparent software development practises. The platform is compatible with various SBOM generation tools and can validate and correct imported SBOMs to improve their accuracy. With the recent addition of the SBOM Quality Score, the key features of SBOM Studio now include:

•    Ingest SBOMs from any source
•    Semantic evaluation of SBOMs
•    SBOM Quality Score
•    Automated SBOM management
•    Accelerated vulnerability management
•    Improved workflow for security operations
•    SBOM sharing and exchange
•    Data-driven business decisions
•    Regulatory compliance and licence infringement
•    VEX functionality

Cytiva - Supor Prime filtersMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024